Service de neurochirurgie, CHU de Clermont Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France; Université Clermont-Auvergne, Clermont-Ferrand, France; SIGMA Clermont, CNRS, Clermont-Ferrand, France.
Service de neurochirurgie, CHU de Clermont Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
Neurochirurgie. 2020 Nov;66(5):365-368. doi: 10.1016/j.neuchi.2020.06.132. Epub 2020 Aug 27.
Subdural empyema (SDE) is a rare complication of chronic subdural hematoma (CSDH) surgery. We introduced antibiotic prophylaxis (AP) for this procedure in 2014 following a morbidity-mortality conference (MMC) in our department. We report the results of retrospective data analysis to assess the effect of systematic AP and to identify risk factors for SDE.
Two hundred eight patients were recruited between January 2013 and December 2015; 5 were excluded for incomplete data: 107 without and 96 with AP (n=203). SDE was confirmed by clinical examination, imaging and bacteriological analysis. Comparisons between AP-(no cefuroxime) and AP+ (cefuroxime) groups were made with Chi test and Student's t-test.
One empyema was found in each group, indicating that AP had no effect (P=1). The only criterion associated with SDE for these two patients was a greater number of reoperations for CSDH recurrence (P=0.013).
The incidence of postoperative empyema was 1%, similar to the range of 0.2%-2.1% reported in the literature. This rare incidence explains why we found no significant effect of AP. The medical decision taken at the MMC did not help to reduce the rate of postoperative SDE. MMCs can help to define factors associated with adverse surgical events and identify opportunities for improvement.
AP, introduced after an MMC, did not impact SDE rates. In practice, AP should be required only in case of reoperation for CSDH recurrence. However, we still continue to use AP following the MMC considering different parameters discussed in the manuscript.
硬脑膜下积脓(SDE)是慢性硬脑膜下血肿(CSDH)手术后罕见的并发症。我们在 2014 年的一次科室发病率-死亡率会议(MMC)之后,为该手术引入了抗生素预防(AP)。我们报告回顾性数据分析的结果,以评估系统 AP 的效果,并确定 SDE 的危险因素。
2013 年 1 月至 2015 年 12 月期间,共招募了 208 名患者;5 名患者因数据不完整而被排除在外:107 名未接受 AP 和 96 名接受 AP(n=203)。SDE 通过临床检查、影像学和细菌学分析确认。使用卡方检验和学生 t 检验比较 AP-(无头孢呋辛)和 AP+(头孢呋辛)组之间的差异。
每组均发现 1 例积脓,表明 AP 没有效果(P=1)。对于这两名患者,唯一与 SDE 相关的标准是 CSDH 复发的再手术次数更多(P=0.013)。
术后积脓的发生率为 1%,与文献报道的 0.2%-2.1%的范围相似。这种罕见的发生率解释了为什么我们没有发现 AP 的显著效果。MMC 做出的医疗决策并没有帮助降低术后 SDE 的发生率。MMC 可以帮助确定与不良手术事件相关的因素,并确定改进的机会。
AP 在 MMC 后引入,并未影响 SDE 的发生率。在实践中,只有在 CSDH 复发时需要进行再次手术时,才需要使用 AP。然而,考虑到本文中讨论的不同参数,我们仍然继续在 MMC 后使用 AP。